(Q64047271)
Statements
A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes With Inadequate Glycaemic Control on Insulin (English)
0 references
April 2008
0 references
May 2009
0 references
1,240
0 references
18 year
0 references
80 year
0 references